Study establishes new perioperative standard in prostate cancer
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide – a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) – plus hormone…